Business- Page 41

Late-breaking oral presentation to highlight efficacy data across tumor types and in the ovarian cancer primary analysis population PRINCETON, N.J., Nov. 04, 2026 (GLOBE NEWSWIRE) — PMV Pharmaceuticals, Inc. (“PMV Pharma” or

BOSTON, Nov. 04, 2026 (GLOBE NEWSWIRE) — Elicio Therapeutics, Inc. (Nasdaq: ELTX) (“Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced that it will host

— Expanded guidance based on additional evidence demonstrating the benefits of IMCIVREE in adults living with Bardet-Biedl syndrome — BOSTON, Nov. 04, 2026 (GLOBE NEWSWIRE) — Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global

Wilmington, Del., Nov. 04, 2026 (GLOBE NEWSWIRE) — Global Indemnity Group, LLC (Nasdaq: GBLI) (the “Company”) today reported financial results for the three and nine months ended September 30, 2026. For the

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) — Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced

MILWAUKEE, Nov. 04, 2026 (GLOBE NEWSWIRE) — Twin Disc, Inc. (NASDAQ: TWIN) today reported results for the first quarter ended September 25, 2026. Fiscal First Quarter 2027 Highlights Sales increased 10.9% year-over-year

Potent, selective TSHR NAM with pre-clinical activity demonstrated across biochemical, thyroid and ocular endpoints Favorable PK profile anticipated to support once-daily oral dosing in humans Phase 1 clinical trial initiation planned for

REDWOOD CITY, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) — Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper” or the “Company”), a clinical stage biotechnology company focused on the design and development of innovative therapies